[1]
|
USP, “Monograph of Naproxen Sodium,” 34th Edition, United States Pharmacopoeial Convention, Rockville, 2011.
|
[2]
|
ICH, “Stability Testing of New Drug Substances and Products,” International Conference on Harmonization Guidance Documents, Q1A (R2), 2005.
|
[3]
|
ICH, “Impurities in New Drug Substances,” International Conference on Harmonization Guidance Documents, Q3A (R1), 2006.
|
[4]
|
ICH, “Impurities in New Drug Products,” International Conference on Harmonization Guidance Documents, Q3B (R1), 2006.
|
[5]
|
EP, “Monograph of Naproxen Sodium,” 7th Edition, European Pharmacopeia Guideline Document, 2011.
|
[6]
|
J. Peter, Harrington and E. Lodewijk, “Twenty Years of Naproxen Technology,” Organic Process Research and Development, Vol. 1, No. 1, 1997, pp. 72-76.
doi:10.1021/op960009e
|
[7]
|
H. Zhu and M. A. Bo, “Asymmetric Hydrogenation Synthesis of –(S)-(+)-2-(6’-Methoxyl-2-naphthyl) Propionic Acid by Cinchona Modified Pd (0)-α-FeOOH Catalyst,” Chinese Chemical Letters, Vol. 14, 2003, pp. 1101-1104.
|
[8]
|
A. Ekpe, J. H. Tong and L. Rodriguez, “High-Performance Liquid Chromatographic Method Development and Validation for the Simultaneous Quantitation of Naproxen Sodium and Pseudoephedrine Hydrochloride Impurities,” Journal of Chromatographic Science, Vol. 39, 2001, p. 81. doi:10.1093/chromsci/39.3.81
|
[9]
|
E. Dinc, A. Ozdemir, H. Aksoy, O. Ustundag and D. Baleanu, “Chemometric Determination of Naproxen Sodium and Pseudoephedrine Hydro Chloride in Tablets by HPLC,” Chemical and Pharmaceutical Bulletin, Vol. 54, 2006, p. 415. doi:10.1248/cpb.54.415
|
[10]
|
L. Monser and F. Darghouth, “Simultaneous Determination of Naproxen and Related Compounds by HPLC Using Porus Graphitic Carbon Column,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 32, 2003, p. 1087. doi:10.1016/S0731-7085(03)00213-9
|
[11]
|
B. M. Tashtoush and B. M. Al-Taani, “HPLC Determination of Naproxen in Plasma,” Die Pharmazie, Vol. 58, 2003, p. 614.
|
[12]
|
F. Nielsen-Kudsk, “HPLC Determination of Some Anti- Inflammatory, Weak Analgesic and Uricosuric Drugs in Human Blood Plasma and Its Application to Pharmacokinetics,” Acta Pharmacol Toxicol, Vol. 47, 1980, p. 267.
doi:10.1111/j.1600-0773.1980.tb03653.x
|
[13]
|
T. M. Phillips and E. F. Wellner, “Measurement of Naproxen in Human Plasma by Chip-Based Immunoaffinity Capillary Electrophoresis,” Biomedical Chromatography, Vol. 20, 2006, p. 662. doi:10.1002/bmc.673
|
[14]
|
E. Mikami, T. Goto, T. Ohno, H. Matsumoto and M. Nishida, “Simultaneous Analysis of Naproxen, Nabumetone and Its Major Metabolite 6-Methoxy-n-Napthyl Acetic Acid in Pharmaceuticals and Human Urine by HPLC,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 23, 2000, p. 917. doi:10.1016/S0731-7085(00)00365-4
|
[15]
|
P. Zakeri_Milani, M. Barzegar-Jalali, H. Tajerzadeh, Y. Azrmi and H. Valizadesh, “Simultaneous Determination of Naproxen, Ketoprofen and Phenol Red in Samples from Rat Intestinal Permeability Studies HPLC Method Development and Validation,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 39, 2005, p. 624.
doi:10.1016/j.jpba.2005.04.008
|
[16]
|
Y. Hsu, Y. Liou, J. Lee, C. Chen and A. Wu, “Assay of Naproxen by High-Performance Liquid Chromatography and Identification of Its Photo Products by LC-ESI/MS,” Biomedical Chromatography, Vol. 20, 2006, p. 787.
doi:10.1002/bmc.598
|
[17]
|
ICH, “Validation of Analytical Procedures: Text and Methodology,” International Conference on Harmonization Guidance Documents, Q2 (R1), 2005.
|